Candriam S.C.A.
Institutional investor · Portfolio as of Q1 2019
Top Holdings788 positions
Microsoft Corp | 1.7M | $205M | 2.6% | $110.12 | 0.00% | 1 qtr | First report 0 |
Amgen Inc | 1M | $194.2M | 2.5% | $151.37 | 0.00% | 1 qtr | First report 0 |
Biogen Inc | 654,495 | $154.7M | 2.0% | $236.38 | 0.00% | 1 qtr | First report 0 |
Apple Inc | 758,114 | $149.9M | 1.9% | $45.22 | 0.00% | 1 qtr | First report 0 |
Regeneron Pharmaceuticals Inc | 347,271 | $142.6M | 1.8% | $406.78 | 0.00% | 1 qtr | First report 0 |
Alphabet Inc | 119,297 | $141.6M | 1.8% | $58.29 | 0.00% | 1 qtr | First report 0 |
Amazon.com Inc | 74,359 | $132.4M | 1.7% | $89.04 | 0.00% | 1 qtr | First report 0 |
Gilead Sciences Inc | 2M | $131.1M | 1.7% | $49.25 | 0.00% | 1 qtr | First report 0 |
Merck & Co Inc | 1.6M | $130.4M | 1.7% | $63.02 | 0.00% | 1 qtr | First report 0 |
Alibaba Group Holding Ltd | 682,348 | $124.5M | 1.6% | $171.70 | 0.00% | 1 qtr | First report 0 |
Vertex Pharmaceuticals Inc | 661,520 | $121.7M | 1.6% | $183.95 | 0.00% | 1 qtr | First report 0 |
Celgene Corp | 1.3M | $118.1M | 1.5% | — | — | 1 qtr | First report 0 |
Facebook Inc | 566,232 | $94.4M | 1.2% | $165.11 | 0.00% | 1 qtr | First report 0 |
Bristol-Myers Squibb Co | 2M | $94.1M | 1.2% | $35.91 | 0.00% | 1 qtr | First report 0 |
Procter & Gamble Co/The | 722,938 | $79M | 1.0% | $85.93 | 0.00% | 1 qtr | First report 0 |
Walt Disney Co/The | 671,243 | $78.6M | 1.0% | $106.35 | 0.00% | 1 qtr | First report 0 |
Alexion Pharmaceuticals Inc | 565,052 | $76.4M | 1.0% | — | — | 1 qtr | First report 0 |
Visa Inc | 444,154 | $73M | 0.9% | $148.12 | 0.00% | 1 qtr | First report 0 |
Exxon Mobil Corp | 812,065 | $71.8M | 0.9% | $58.62 | 0.00% | 1 qtr | First report 0 |
Illumina Inc | 230,410 | $71.6M | 0.9% | $302.23 | 0.00% | 1 qtr | First report 0 |
Candriam S.C.A. manages $7.8B across 788 positions as of Q1 2019. Top holdings: MSFT (2.6%), AMGN (2.5%), BIIB (2.0%). Fund DNA: Steady Compounder. HoldingsIntel Score: 2.5/5.0.
First quarter we have for this fund: 788 positions, nothing earlier to compare. No standout high-conviction moves this quarter. Portfolio: $7.8B across 788 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR